196 related articles for article (PubMed ID: 27211282)
1. Evaluation of the Relationship Between Hb F Levels and Nucleated Red Blood Cells with Morbidity in Non Transfusion-Dependent Thalassemia Patients.
Karimi M; Jooya P; Haghpanah S; Mokhtari M; Rezaei N; Fath M; Parand S
Hemoglobin; 2016 Aug; 40(4):250-6. PubMed ID: 27211282
[TBL] [Abstract][Full Text] [Related]
2. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
El-Beshlawy A; El-Ghamrawy M; EL-Ela MA; Said F; Adolf S; Abdel-Razek AR; Magdy RI; Abdel-Salam A
Ann Hematol; 2014 Dec; 93(12):2045-50. PubMed ID: 25062719
[TBL] [Abstract][Full Text] [Related]
3. Beta-Thalassemia Intermedia: A Single Thalassemia Center Experience from Northeastern Iraq.
Amin SS; Jalal SD; Ali KM; Mohammed AI; Rasool LK; Osman TJ
Biomed Res Int; 2020; 2020():2807120. PubMed ID: 32190657
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Molecular Characteristics of Non-Transfusion-Dependent Thalassemia in Kuwait.
Adekile AD; Azab AF; Al-Sharida SI; Al-Nafisi BA; Akbulut N; Marouf RA; Mustafa NY
Hemoglobin; 2015; 39(5):320-6. PubMed ID: 26076396
[TBL] [Abstract][Full Text] [Related]
5. Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia.
Musallam KM; Cappellini MD; Wood JC; Motta I; Graziadei G; Tamim H; Taher AT
Haematologica; 2011 Nov; 96(11):1605-12. PubMed ID: 21791471
[TBL] [Abstract][Full Text] [Related]
6. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
Yavarian M; Karimi M; Bakker E; Harteveld CL; Giordano PC
Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease.
Fucharoen S; Siritanaratkul N; Winichagoon P; Chowthaworn J; Siriboon W; Muangsup W; Chaicharoen S; Poolsup N; Chindavijak B; Pootrakul P; Piankijagum A; Schechter AN; Rodgers GP
Blood; 1996 Feb; 87(3):887-92. PubMed ID: 8562958
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
Alebouyeh M; Moussavi F; Haddad-Deylami H; Vossough P
Ann Hematol; 2004 Jul; 83(7):430-3. PubMed ID: 14722738
[TBL] [Abstract][Full Text] [Related]
9. A prospective analysis for prevalence of complications in Thai nontransfusion-dependent Hb E/β-thalassemia and α-thalassemia (Hb H disease).
Ekwattanakit S; Siritanaratkul N; Viprakasit V
Am J Hematol; 2018 May; 93(5):623-629. PubMed ID: 29359464
[TBL] [Abstract][Full Text] [Related]
10. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.
Kosaryan M; Karami H; Zafari M; Yaghobi N
Hemoglobin; 2014; 38(2):115-8. PubMed ID: 24471558
[TBL] [Abstract][Full Text] [Related]
11. Complications of β-thalassemia intermedia in Iran during 1996-2010 (single-center study).
Rafsanjani KA; Mafi N; Tafreshi RI
Pediatr Hematol Oncol; 2011 Sep; 28(6):497-508. PubMed ID: 21728720
[TBL] [Abstract][Full Text] [Related]
12. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia.
Karimi M; Mohammadi F; Behmanesh F; Samani SM; Borzouee M; Amoozgar H; Haghpanah S
Eur J Haematol; 2010 Jan; 84(1):52-8. PubMed ID: 19799627
[TBL] [Abstract][Full Text] [Related]
13. Relationship Between Serum Hepcidin and Ferritin Levels in Patients With Thalassemia Major and Intermedia in Southern Iran.
Haghpanah S; Esmaeilzadeh M; Honar N; Hassani F; Dehbozorgian J; Rezaei N; Abdollahi M; Bardestani M; Safaei S; Karimi M
Iran Red Crescent Med J; 2015 Jul; 17(7):e28343. PubMed ID: 26421179
[TBL] [Abstract][Full Text] [Related]
14. Response to hydroxyurea therapy in beta-thalassemia.
Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
[TBL] [Abstract][Full Text] [Related]
15. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran.
Karimi M; Darzi H; Yavarian M
J Pediatr Hematol Oncol; 2005 Jul; 27(7):380-5. PubMed ID: 16012328
[TBL] [Abstract][Full Text] [Related]
16. Serum angiogenin level in sickle cell disease and beta thalassemia patients.
Matter RM; Abdelmaksoud AA; Shams MA; Bebawy EK
Pediatr Hematol Oncol; 2014 Feb; 31(1):50-6. PubMed ID: 24483841
[TBL] [Abstract][Full Text] [Related]
17. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.
Bradai M; Pissard S; Abad MT; Dechartres A; Ribeil JA; Landais P; de Montalembert M
Transfusion; 2007 Oct; 47(10):1830-6. PubMed ID: 17880608
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia.
Hoppe C; Vichinsky E; Lewis B; Foote D; Styles L
Am J Hematol; 1999 Dec; 62(4):221-7. PubMed ID: 10589077
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia.
Haghpanah S; Zarei T; Eshghi P; Zekavat O; Bordbar M; Hoormand M; Karimi M
Ann Hematol; 2018 Oct; 97(10):1919-1924. PubMed ID: 29926158
[TBL] [Abstract][Full Text] [Related]
20. Frequency and distribution of asymptomatic brain lesions in patients with β-thalassemia intermedia.
Karimi M; Haghpanah S; Bagheri MH; Bordbar MR; Pishdad P; Rachmilewitz EA
Ann Hematol; 2012 Dec; 91(12):1833-8. PubMed ID: 22824997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
